Skip to search formSkip to main contentSkip to account menu

tipranavir

Known as: 3'-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2h-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide, tipranavir [Chemical/Ingredient] 
A non-peptidomimetic agent that inhibits both wild type and drug resistant forms of human immunodeficiency virus (HIV) protease.
National Institutes of Health

Related topics

Related topics

7 relations

Broader (3)

Anti-HIV AgentsPyridinesPyrones
HIV Protease Inhibitors [MoA]Tipranavir:MCnc:Pt:Ser:QnTipranavir:Susc:Pt:Isolate:OrdQn

Narrower (1)

PNU 140690

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Efficacy of new antiretroviral drugs in treatment‐experienced HIV‐infected patients: a systematic review and meta‐analysis of recent randomized controlled trials
We performed a systematic review and meta‐analysis of randomized controlled trials (RCTs) to assess the overall efficacy of new… 
2010
2010
HIV-1 non-B subtypes: High transmitted NNRTI-resistance in Spain and impaired genotypic resistance interpretation due to variability.
2009
2009
Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients
Among the 3700 HIV-infected patients followed in our institution, 17 with regular clinical, immunological and virological follow… 
2009
2009
Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass…
2009
2009
Improving the Oral Absorption of Poorly Soluble Drugs Using SEDDS and S-SEDDS Formulations
2008
2008
Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes
Background:Tipranavir (TPV) and darunavir (DRV) are potent against protease inhibitor (PI)-resistant viruses. Efficacy of these… 
Highly Cited
2006
Highly Cited
2006
Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
BACKGROUND Current protease inhibitors (PIs) are designed against HIV-1, and information on their performance against HIV-2… 
2006
2006
Unexpected drug–drug interaction between tipranavir/ritonavir and enfuvirtide
Fifty-five patients placed on tipranavir/ritonavir 500/200 mg twice a day (27 with enfuvirtide and 28 without) underwent… 
Highly Cited
2004
Highly Cited
2004
Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers
Abstract Purpose: To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir… 
2004
2004
A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1–Infected Patients
Abstract:Tipranavir (TPV), a novel nonpeptidic protease inhibitor (NPPI), was administered to treatment-naive HIV-1–infected… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)